Advice
following an abbreviated submission:
bevacizumab gamma (Lytenava®) is accepted for use within NHSScotland.
Indication under review: in adults for treatment of neovascular (wet) age-related macular degeneration (nAMD).
Bevacizumab gamma offers an additional treatment choice in the therapeutic class of vascular endothelial growth factor inhibitors.
This advice applies only in the context of an approved NHSScotland Patient Access Scheme (PAS) arrangement delivering the cost-effectiveness results upon which the decision was based, or a PAS/ list price that is equivalent or lower.
Download detailed advice279KB (PDF)
Medicine details
- Medicine name:
- bevacizumab gamma (Lytenava)
- SMC ID:
- SMC2744
- Indication:
In adults for treatment of neovascular (wet) age-related macular degeneration (nAMD)
- Pharmaceutical company
- Outlook Therapeutics Ltd
- BNF chapter
- Eye
- Submission type
- Abbreviated
- Status
- Accepted
- Date advice published
- 09 June 2025